Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

US Market Product Portfolio for Immunology Drugs 2018 - Research and Markets

Research and Markets
Posted on: 02 Nov 17

The "US Market Product Portfolio for Immunology Drugs 2018 - MedFolio" report has been added to Research and Markets' offering.

The full report suite is an extensive market analysis study on the current biologics such as ORENCIA, HUMIRA, CIMZIA, Enbrel, SIMPONI, REMICADE, RITUXAN, Actemra, STELARA, ENTYVIO and TYSABRI. The others segment includes XELJANZ, promising biologics in pipeline consisting of JAK inhibitors (imposing competition to XELJANZ) and other TNF and interleukin biologics that will enter the market during the forecast period.

Some of these biologics are approved and used in more than one conditions. Therefore, the market is segmented by diseases. The report comprises market analyses on rheumatoid arthritis, ankylosing spondylitis, Crohn`s disease, ulcerative colitis and psoriasis drugs globally.

The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases.

Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. The reports covers second line treatments, their dosage, comparative cost studies, market size and revenue forecasts.

Key Topics Covered:

Executive Summary

1. Version History

2. 9-Step Methodology

3. Mechanism of Action

3.1 Introduction

3.1.1 Tumor Necrosis Factor (Tnf)

3.1.2 B-Cell Inhibitors

3.1.3 Interleukin Inhibitors

3.1.4 Janus Kinase Inhibitors

3.1.5 Co-Stimulation Modulators

4. Product Assessment

4.1 Key Marketed Products

4.1.1 Abatacept (Orencia)

4.1.2 Adalimumab (Humira)

4.1.3 Certolizumab Pegol (Cimzia)

4.1.4 Etanercept (Enbrel, Benepali)

4.1.5 Golimumab (Simponi)

4.1.6 Infliximab (Remicade, Inflectra, Remsima, Flixabi, Renflexis)

4.1.7 Natalizumab (Tysabri)

4.1.8 Rituximab (Rituxan, Mabthera, Rixathon, Truxima)

4.1.9 Tocilizumab (Actemra/Roactemra)

4.1.10 Tofacitinib (Xeljanz)

4.1.11 Ustekinumab (Stelara)

4.1.12 Vedolizumab (Entyvio)

4.2 Key Products in Pipeline

4.2.1 Barcitinb (Olumiant)

4.2.2 Guselkumab (Tremfya)

4.2.3 Cobitolimod (Kappaproct)

4.2.4 Mavrilimumab

4.2.5 Sirukumab

4.2.6 Vobarilizumab

4.3 Products in Development By Core Companies

4.4 Clinical Trial By Disease

5. Country Profile

6. Company Profiles

6.1 Abbvie Inc.

6.2 Amgen Inc.

6.3 Biogen Idec

6.4 Bristol-Myers Squibb

6.5 Hoffmann-La Roche Ltd

6.6 Johnson & Johnson/Janssen

6.7 Novartis Ag

6.8 Pfizer Inc.

6.9 Takeda Pharmaceutical Company Limited

6.10 Ucb S.A.

For more information about this report visit

View source version on

Business Wire

Last updated on: 02/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.